Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non–small-cell lung cancer (NSCLC) with PD-L1 expression are not known.